OMNIPRED Drug Patent Profile
✉ Email this page to a colleague
When do Omnipred patents expire, and when can generic versions of Omnipred launch?
Omnipred is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in OMNIPRED is prednisolone acetate. There are eighty-eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the prednisolone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Omnipred
A generic version of OMNIPRED was approved as prednisolone acetate by LUPIN LTD on August 2nd, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMNIPRED?
- What are the global sales for OMNIPRED?
- What is Average Wholesale Price for OMNIPRED?
Summary for OMNIPRED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,102 |
| What excipients (inactive ingredients) are in OMNIPRED? | OMNIPRED excipients list |
| DailyMed Link: | OMNIPRED at DailyMed |
Recent Clinical Trials for OMNIPRED
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 4 |
| Oregon Health and Science University | Phase 4 |
| University of California, San Francisco | Phase 4 |
US Patents and Regulatory Information for OMNIPRED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | OMNIPRED | prednisolone acetate | SUSPENSION/DROPS;OPHTHALMIC | 017469-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
